Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade A 320.14 -0.77% -2.47
BIIB closed down 0.77 percent on Thursday, December 13, 2018, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Down
See historical BIIB trend table...

Date Alert Name Type % Chg
Dec 13 50 DMA Resistance Bearish 0.00%
Dec 13 Fell Below 20 DMA Bearish 0.00%
Dec 13 NR7 Range Contraction 0.00%
Dec 12 50 DMA Resistance Bearish -0.77%
Dec 12 Crossed Above 20 DMA Bullish -0.77%
Dec 12 Pocket Pivot Bullish Swing Setup -0.77%
Dec 12 Up 3 Days in a Row Strength -0.77%
Dec 11 20 DMA Resistance Bearish 0.11%
Dec 11 50 DMA Resistance Bearish 0.11%
Dec 11 MACD Bearish Centerline Cross Bearish 0.11%

Older signals for BIIB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 388.67
52 Week Low 249.17
Average Volume 1,244,609
200-Day Moving Average 312.0315
50-Day Moving Average 323.1404
20-Day Moving Average 322.493
10-Day Moving Average 324.066
Average True Range 9.5275
ADX 13.6
+DI 19.4503
-DI 19.3762
Chandelier Exit (Long, 3 ATRs ) 310.1375
Chandelier Exit (Short, 3 ATRs ) 338.5825
Upper Bollinger Band 333.1945
Lower Bollinger Band 311.7915
Percent B (%b) 0.39
BandWidth 6.636733
MACD Line -0.2538
MACD Signal Line 0.1378
MACD Histogram -0.3916
Fundamentals Value
Market Cap 67.69 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 21.01
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 330.18
Resistance 3 (R3) 330.91 328.30 328.50
Resistance 2 (R2) 328.30 325.74 327.93 327.94
Resistance 1 (R1) 324.22 324.17 322.92 323.49 327.39
Pivot Point 321.61 321.61 320.96 321.24 321.61
Support 1 (S1) 317.53 319.05 316.23 316.80 312.89
Support 2 (S2) 314.92 317.48 314.55 312.34
Support 3 (S3) 310.84 314.92 311.78
Support 4 (S4) 310.11